Novartis (NVS) Announces Promising Data on Tasigna & Hyrimoz
Novartis (NVS) announces positi.....»»
Novartis Announces Positive Data on Kisqali and Tasigna
Novartis (NVS) announces positive data on breast cancer drug Kisqali and oncology drug Tasigna at the ASCO. Novartis NVS presented posi.....»»
Novartis drops 1.5% to $89.33 after FDA announces gene therapy data issue
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis Reports Data on Cosentyx for Psoriatic Arthritis
Novartis (NVS) announces new data .....»»
Novartis announces new early stage histology data in kidney transplantation
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis (NVS) Announces Various Data Presentations at ASCO
Novartis (NVS) announces a number of data presentations at.....»»
Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations. Want the.....»»
Novartis (NVS) Reports Encouraging Data on MS Candidate
Novartis (NVS) announces encouraging .....»»
Midatech Pharma announces interim data from MTD201 study vs. Novartis" SLAR
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Novartis Presents Positive Data on Sickle Cell Disease Drug
Novartis (NVS) announces.....»»
Novartis Reports Positive Long-Term Data From Cosentyx Trials
Novartis (NVS) announces encouraging five-year data from late-stage studies on Cosentyx for psoriatic arthritis and ankylosing spondylitis indications. Novartis NVS reported encouraging five-year data from ongoing extensions of the .....»»
FDA Approves Novartis" Lutathera As First Therapy For Pediatric Patients With Gastroenteropancreatic Neuroendocrine Tumors
Discover Novartis' FDA approval for Lutathera in pediatric patients with GEP-NETs, marking a pivotal milestone in treating this rare cancer. Explore its efficacy in combating SSTR+ tumors, backed by robust trial data. read more.....»»
Small-Cap Cancer Drug Developer Agenus" Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. Latest Ratings for A.....»»
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Enliven Therapeutics' Phase 1 trial results for ELVN-001 in chronic myeloid leukemia (CML) patients. Explore the promising safety and efficacy data. read more.....»»
Seres Therapeutics announces presentation of Phase 3 Ecospor III study data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Veracyte announces pivotal clinical validation data for nasal swab test
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Sensei Biotherapeutics announces new clinical data from combo trial of SNS-301
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Iovance announces additional clinical data for lifileucel
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Tech company announces layoffs of Jacksonville employees, office closure
A New York-headquartered data and technology firm announced this week it would be laying off 489 employees at its Jacksonville location......»»